ALSO NOTED: Ranbaxy to produce generic Pfizer drug; Keryx triggers big shakeup;

> The weak dollar and the loss of a key patent depressed Boehringer Ingelheim's full-year results; sales grew 3.6 percent, fed mostly by the 30 percent jump in its lung treatment Spiriva. Report

> Less than a month after seeing its lead drug candidate go down in flames in a late-stage trial, Keryx Biopharmaceuticals announced plans to restructure, chopping its workforce in half as it reduces the company's burn rate. Report

> A high-profile crew of biopharma execs are signing on to help promote the life sciences industry in the UK. Report

> Ranbaxy Laboratories got Japanese regulators' blessing for its generic form of Pfizer's angina and blood-pressure med Norvasc. Report

> Australian women with advanced breast cancer will have cheaper access to the GlaxoSmithKline treatment Tykerb as the national drug program adds it to the formulary. Report

> TPG Capital, a U.S. private equity group, is plowing $800 million into SIA International, a Russian pharma distribution company, in exchange for a 50 percent stake. Report

> A stolen Pfizer laptop contained personal info on 800 employees and contractors, including credit card numbers, addresses, and phone numbers; the burgled computer marks the fifth data breach at the drugmaker since January 2007. Report

> Alzheimer's treatment Aricept may be useful for treating stroke and accident victims, aiding memory and concentration, a small study shows. Report

> Funds from non-profit groups are flowing to biotech R&D. Report

And Finally... The ever-growing blogosphere has a new voice--none other than FDA commissioner Andrew von Eschenbach. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.